742,793 Shares in Standard BioTools Inc. $LAB Purchased by Man Group plc

Man Group plc purchased a new stake in shares of Standard BioTools Inc. (NASDAQ:LAB) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 742,793 shares of the company’s stock, valued at approximately $611,000.

A number of other large investors also recently bought and sold shares of LAB. Hsbc Holdings PLC acquired a new stake in shares of Standard BioTools during the 2nd quarter worth approximately $219,000. Primecap Management Co. CA purchased a new position in Standard BioTools in the second quarter valued at $126,000. Sone Capital Management LLC acquired a new position in shares of Standard BioTools in the second quarter worth about $1,755,000. Ieq Capital LLC acquired a new position in shares of Standard BioTools in the second quarter worth about $164,000. Finally, BlackRock Inc. purchased a new stake in shares of Standard BioTools during the 2nd quarter worth about $6,791,000. 53.74% of the stock is owned by institutional investors and hedge funds.

Standard BioTools Stock Performance

NASDAQ:LAB opened at $0.67 on Friday. The stock has a market capitalization of $264.56 million, a PE ratio of 3.06 and a beta of 1.37. Standard BioTools Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $1.72. The company has a fifty day moving average of $0.79 and a two-hundred day moving average of $0.91.

Standard BioTools (NASDAQ:LAB) last released its earnings results on Wednesday, August 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). Standard BioTools had a negative return on equity of 7.57% and a net margin of 100.36%.The company had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $20.80 million.

Analyst Ratings Changes

Separately, Weiss Ratings cut Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $1.35.

Standard BioTools Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.